Nabla vs Recursion Pharmaceuticals

By valuation, Recursion Pharmaceuticals is the larger company at $2.2B versus $180M — a 12.1x difference. Size can also be measured by team: Nabla employs 80 people while Recursion Pharmaceuticals has 800 employees.

Nabla has raised $30M in disclosed funding across 1 known round. Recursion Pharmaceuticals's funding history is not publicly available.

Nabla holds the higher Awaira Score at 73/100, compared to Recursion Pharmaceuticals's 65/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 8-point gap that reflects meaningful differences in scale or traction.

Nabla was founded by Alexandre Lebrun in 2018. Recursion Pharmaceuticals was founded by Chris Gibson in 2013. Visit each company's profile on Awaira for a full founder biography.

Nabla: Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows. The company has raised $30M in total funding and operates at Series B stage with a valuation of $200M. Nabla's core offering focuses on AI-powered clinical documentation tools designed to reduce administrative burden on healthcare providers. The platform leverages natural language processing and machine learning to automate medical note-taking, allowing physicians to spend more time with patients rather than on paperwork. The company targets hospitals, clinics, and healthcare systems across Europe, with particular strength in the French market. Nabla's technology integrates with existing electronic health record systems and clinical workflows. The company competes in the growing digital health and healthcare AI sector alongside players focused on clinical automation and documentation efficiency. Nabla's approach emphasizes practical integration into existing healthcare infrastructure rather than building standalone applications. The company has demonstrated traction in European healthcare markets where administrative burden on clinicians remains significant. Its Series B funding stage indicates successful product-market fit validation and positions Nabla for expanded market reach and product development in the healthcare AI space. Nabla addresses the specific pain point of clinical documentation burden through AI automation, allowing European healthcare providers to improve operational efficiency. Recursion Pharmaceuticals: Recursion Pharmaceuticals is a computational biology company founded in 2013 that uses artificial intelligence and high-throughput screening to accelerate drug discovery and development. The company's platform combines automated microscopy, machine learning, and large-scale biological data analysis to identify novel drug candidates and therapeutic targets across multiple disease areas. Recursion operates a proprietary laboratory automation system capable of conducting millions of experiments to map cellular and molecular responses to chemical compounds. The company has developed computational models to predict drug efficacy and safety profiles before traditional clinical testing, significantly reducing development timelines and costs. As a publicly traded company with a $2.2 billion valuation, Recursion has built partnerships with major pharmaceutical firms including Bayer and Exscientia to validate its platform's effectiveness. The company's approach focuses on rare genetic diseases and oncology, leveraging its ability to process vast biological datasets that would be impractical through conventional methods. Recursion's competitive advantage lies in its integration of wet laboratory automation with advanced machine learning analytics, enabling systematic drug discovery at scale. The company continues to expand its internal pipeline while licensing its technology to established pharma players, positioning itself as both a drug developer and a computational biology platform provider in the AI healthcare sector. Recursion combines automated laboratory systems with machine learning to systematize drug discovery at unprecedented scale and speed.

Recursion Pharmaceuticals was founded first in 2013, giving it 5 years of additional market experience. Nabla was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Nabla has approximately 80 employees, while Recursion Pharmaceuticals has approximately 800. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Nabla and Recursion Pharmaceuticals are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.